Article info
PDFNeurological rarities
Giant cell myositis responsive to combined corticosteroids and immunoglobulin
Citation
Giant cell myositis responsive to combined corticosteroids and immunoglobulin
Publication history
- Accepted June 20, 2015
- First published July 22, 2015.
Online issue publication
April 14, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Other content recommended for you
- Morvan’s fibrillary chorea: a paraneoplastic manifestation of thymoma
- Giant cell myositis associated with metastatic thymoma and granulomatous hypercalcaemia
- Neuromyelitis optica and myasthenia gravis in a young Nigerian girl
- Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis
- 68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis
- Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease
- Overlooked non-motor symptoms in myasthenia gravis
- Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
- Fulminant immune-mediated necrotising myopathy (IMNM) mimicking myocardial infarction with non-obstructive coronary arteries (MINOCA)